Form 8-K

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FgR8zv0LdE+AnOwDIXFeZyFcLSJ7ovx66dVWhLN88ESbmDFw0aukTFdJFZaTZfnM iBicxBeaqePI98EX/0cZ7Q== 0001193125-05-033909.txt : 20050222 0001193125-05-033909.hdr.sgml : 20050221 20050222110637 ACCESSION NUMBER: 0001193125-05-033909 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20050222 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20050222 DATE AS OF CHANGE: 20050222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANTARES PHARMA INC CENTRAL INDEX KEY: 0001016169 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411350192 STATE OF INCORPORATION: MN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32302 FILM NUMBER: 05629780 BUSINESS ADDRESS: STREET 1: 707 EAGLEVIEW BOULEVARD STREET 2: SUITE 414 CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 610-458-6200 MAIL ADDRESS: STREET 1: 707 EAGLEVIEW BOULEVARD STREET 2: SUITE 414 CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC /MN/ DATE OF NAME CHANGE: 20010604 FORMER COMPANY: FORMER CONFORMED NAME: MEDI JECT CORP /MN/ DATE OF NAME CHANGE: 19960605 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) February 22, 2005

ANTARES PHARMA, INC.

(Exact Name of Registrant as Specified in Charter)

Minnesota

0-20945

41-1350192

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)


707 Eagleview Boulevard, Suite 414, Exton, PA		19341
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code (610) 458-6200

n/a

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On February 22, 2005, Antares Pharma, Inc. issued a press release announcing its intention to host a conference call for investors and analysts on Friday, February 25, 2005 at 8:30 a.m. EST to provide an update on progress made under Antares’ development agreement with Eli Lilly and Company. A copy of this press release is attached hereto as Exhibit 99.1. The information in Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Item 9.01. Financial Statements and Exhibits.

(c)

Exhibits.


99.1		Press Release dated February 22, 2005*

*	Such press release being “furnished” and not “filed.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: February 22, 2005	By	/s/ Lawrence M. Christian
		Lawrence M. Christian
	Its	Chief Financial Officer

EX-99.1 2 dex991.htm PRESS RELEASE Press Release

Exhibit 99.1

LOGO

For further information, contact:


Jack E. Stover	President and CEO	610-458-6200
Lawrence M. Christian	CFO and Vice President – Finance	610-458-6200
Steve Chizzik/Ira Weingarten	Equity Communications	805-897-1880

ANTARES PHARMA REPORTS PROGRESS OF NEEDLE-FREE

INJECTION DEVICE DEVELOPMENT PLAN

Company to host conference call on Friday, February 25, 2005, at 8:30 am EST

Exton, Pennsylvania – February 22, 2005 – Antares Pharma, Inc. (Amex®: AIS) announced today that it will host a conference call for investors and analysts on Friday, February 25, 2005, at 8:30 am EST to provide an update on progress made under its development agreement with Eli Lilly and Company. The agreement, signed in September 2003, provides for development of needle-free injection devices for diabetes and obesity patients. The specific key topics expected to be addressed during this call include:

•

The development process for proof-of-concept to date;

•

The successful integration into a viable commercial product;

•

The current status of qualitative and quantitative market research underway; and

•

The next steps in the process and expected timing.

Jack E. Stover, President and CEO of Antares Pharma, commented, “The last formal public communication we had regarding this important relationship was following achievement of a major milestone, the successful outcome of a meeting with the Food and Drug Administration in December 2003, where regulatory expectations for the development program were clarified. We want to take this opportunity to report the significant progress made in the last 14 months and outline potential next steps in the development and commercialization process.”

Analysts and investors can participate in the conference by dialing 1-800-251-4753 (507-726-3480 for international parties). Other interested parties can access a live audio-only Web broadcast from Antares Pharma’s website (www.antarespharma.com). A replay of the Web broadcast will be available until April 8, 2005. A telephone replay will also be available until April 8, 2005, by dialing 1-800-337-4126 (580-431-3012 for international parties). The pass code (0225) will be required for telephonic playback.

About Antares Pharma

Antares Pharma is a specialty pharma company focused on the growing lifestyle products sector and committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new products and devices. The Company’s current technology platforms include transdermal (Advanced Transdermal Delivery ATD^™) gels, disposable mini-needle injection systems (Vibex^™), reusable needle-free injection systems (VISION® and Valeo^™), and fast-melt oral (Easy Tec^™) tablets. The Company currently has active partnering programs with several pharmaceutical and distribution companies for a number of indications and applications, including diabetes, growth disorders, obesity, female sexual dysfunction and other hormone therapy.

Antares Pharma currently distributes its needle-free injector systems in many countries and markets the same technology for use with human growth hormone through licensees in most major regions of the world. Licensees also market an ibuprofen gel using Antares Pharma’s ATD^™ technology in several major European countries. In addition, Antares Pharma is undertaking development or is conducting research on several product opportunities that will form the basis of its specialty pharma program. Antares Pharma’s corporate headquarters is in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company’s reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

For more information, visit Antares Pharma’s web site at www.antarespharma.com and its needle-free product website, www.mediject.com. Information included on the Company’s website is not incorporated herein by reference or otherwise.

GRAPHIC 3 g28496gra1.jpg GRAPHIC begin 644 g28496gra1.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`6@#H`P$1``(1`0,1`?_$`,(``0`"`@(#`0`````` M```````("0$*`@<#!08$`0$```/"2LB0E576UU2979[<8&1$``@$"!`,$!P8$!`<````` M``$"$0,A!`4&,4$247$B$V&!H;$R%`?PD<'10B/A4F+2_X!]6@.M,L0%TLU*DXZA6QU3[ M24R#R,E6Q2`"IVISJ'CG)UD5B(-7I1`AE"@)@#QU7:9:P*7/>;\G=\A]-[H='V,J$L&;^254FI"MV'(=PC)J+\-F9G0G\QD5YN4P;I^E_X!]6@'6;W_`/JT`ZS>_X!]6@'6;W_`/J MT`ZS>_X!]6@'6;W_``#ZM`8'S'\H_KT!C0&#!N`AX#O[]P#\^WCJ6<93@XP= M)-8,43P>*(S\A>/,+F*%5>,B-8N\QR!QAYGT^DKQ,FXEBIL0N9 M1]<)1JJ,U]G,I8GEY/J<)4JL$^X]-Y>>KC1/XUCV%"GURHUAS/U,WKR/= MMW\>Z+333?IH6V<9N3;3(S9M3;D[;M[XT163;.S']%M:$$"$$7+<.G MTDY$A0_>)!N)MA,7VAK06[-GWM-NO-Y>+^53K1)^'^'N[N&>:-JMO,K]SPS[ M&R9Q1$-PV$VPB`B&^P#[O';RUA#Z9.J:,GHKBZ^!Y-2M4[B5QH-0)1H!H!H! MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H#(^8_E']>@,:`:@Y=*ZEC0&!`!\Q$-P M$!Z1$/`=O\40]VJ667G.?G0ETR8(SGRLC!6=FI$2D2X%J]2=B5),IR^1R+'$I%T7`" M!TE`V`Y!W#70>F9ZWJ]OYO*M7+_=ZV#]:NKE*QF&FH0GUTPP?'D>'G6H^+JBZ>E'ZFD^A'.&SUA,MVCU MDL1RP.P@.PB`#X^/MWU@-NKM4?QIF7)J=M2CB<]*-$E M&-"`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T!D?,?RC^O0&-`-`-`1]Y(\C M\:\8\;R>1J;NU+_2].A@I>*3PBH\Y-^Y+%OAP;5!J6KY;2DE-)]*[6:<7 M)7E#D?E)D>2R!=7HM$%NMO7:FS4.C$5J"344^0CFZ)`34=.$0V%=RN!CKJB8 MVQ0$"AVKM39>G;7TF&G65^XL92[6^./V[C26IZI>UBZ\WF/CP=6W24H;=7EX:R9Y++Q75%XHM;P55Q.)EE2AN*I_I';8I2AXF M.L,I:=GYC,<*'EYV9YDZ>,>$9=*1@%(56L)#-E!`5%E>@155$0 M2;);J*"``&K[M[;>H[IU6WINE\VNJ3X*-5B_X8OVEMU?4\KIMASDZ3Y&G#R@ MY0Y+Y6Y-?Y`R$^(FS(`M:?462S@L)48(%3`FPCFZP]"CE4IRG=.=@5=*AU"( M%`I2]K;2V3IFS(B(F$=Q'Q$1VZAZA`/<&_E[`UE5Y2\I4?[<'5]KKZ>):^JXXX M4Z8G+WB`@```B/4(@4``0`1,8H&$I0$=A'8=M]4OS-GI\QP<;*XRJZ).8YPW>L5W+-XQ7([9N&2AD'#=XF8#(N$E2"4Q5$S[&`=_9KROY& MQF;;M7.$E3%M^\];$[UFYYF7=)\^>'/B6V\:.3;3(S9&EW9V@SO3-$I6KDZJ M2+:T()(``J(FZ"E)*E$HBJB&PF#]LOM#6D-V[/OZ+=>;RL*Y9]E73^'N[N&P MM&U>&8MJU7][M[2:(;CX]0#]`;>_XZU_YMKJZ6FI&2)VY?"9#4S5"62H\#.H M$HT`T`T`T!ZR8F(N`C7TS.2<="0L6S<2$M,R[UM&Q46P:D]1P]?R#Q1)HS;( M)@)CJ*'*0A0$1$`#?0'YJS9JY=8&+M-/L,%:JU,M@>1%CK,LPGH"8:=9D_FH MN8BUW4>_;"H0Q>M)0Q>HHAON&@/>:`:`:`:`:`:`:`:`:`R/F/Y1_7H#@8P% M\_S;>(CJ,4Y.B)HPNM]:BVJ<:^PTX>3O)_(_*[([S(5]?"1JF;TZE4&;EPG"5&%$X MF1CF#8Q^@[@Q#"+ERH3UG*VYC"!>DI>UMK;+TK:ND6\KD(_^1IXY]K[:\?51 M)7T:RRW-?!<=)1XM\_7 MS++&,7+IC@O29`0+N)A*4H!N8QC;`4.HH"(_0&_Z=@\Q`-2WYQ\B:@T\,6N2 M[63OP0E%-.35,"]CML=M9:YJ07(/D+`*MZ<@JVD\=8ZF4#IGM*B9O6:6NTL% MRE50@DE2E48M%-A=_P`10OIB4#%<.!=KGWCS7\O0A5F*+.%ND4U!*"F2(@BV4 M10`/0B94J*0F4C1`H`40+U(@`=.P;AK2FUMV3T:XH3F[F5?Q+B^]5YOFN?'B M9OJ^CO/VVX.$94]?N*SWW%W/+%TNT''DH\!N<4RNHYQ'.6:Y0^RH@O\`.@*A M#![1\??XZW-D][[:S&6\YYB-MK],\)>I*J[L3"O_`%[4K,>F%N4XKF>N4XWY MV1VZ\76Z8/.07ZJX\N3P])3RTO5J],;%R M/:VL*>JIY&>`\_1[MJ^8XWN;)TQ7*Z:.6B+9)TW=)_PED5@=@9,Y!\MM39C= MVWLU;\F]F\O*W3FW_:55O3=3RZ4LM"2N>FI:_@"RY.GZB".5ZJ\K=EB52,0= M.P01_M`U!`ITY,&R2JHI.0WZ%_(HG\0UHW<>1TVWF?,TRY&=INN&/3Z*]CY+ M\#.M.G=DZ7#OOKY-4PQ^W`O-SBNXAOS"[@W#K@/38V[\L\Z5' M$49/+.VU5BI4[R4MUQ2R%9R/9'#9I4ZSF2B7W"J]O>O!$&;"L/\E5VN14L_>F M#I10(OZRQQ`A"F.(%$"V^V6F#HU4LUVM+T(JM4^O3%IL4BHDJL$=!P$_4J\XNE;DLU;'>G;5`]]@()E8'JK-,RJ3=!4SA9 M,HB0AMAV`^`[X'<)XA\4^)&;\$9]RLWHV3N2G&;.D1AJLK5RS30W.0"JNJ[\ MJF^A(B1C8X1F)ILB(O%4"!ZN^^P#H"OS\/=W4(F`"=%BV7,D!BB?I`0' M0%=N$_Q$?:1SMDB#Q56^3HTZV6IT@QJ1LPXVR3B"N6AZZ73;,VL-;,@5>"K: MJKQ94I4?4HY`,!=9\VD*?J%ZC%Z>L`+TB8Q?3,KN4`,(&_=E$?# M]>@*S`[RO;6)QCE>8CWE'38CC[&7VPXM1N1$?2VCIXS6FYY&W)1+R#0!PQ4*4KE-,Y]R](#UEW`JC6_$X=GU&S*0I< M\7]S64I_KVP>+>3Y_#%USG-7O)U.<&9WBJX-QK?,SJT=ZDN"#IA; M)>B028GW!=J=V+E(Q3$,3K*)0`F%PR[B'#?N!U"3N7$W.%8RDWKQD4K M96T4Y"O7VF.'&WH(6VAV5G%6N"%8P])%%FH(*'*8I5!,4P`!-4WF/Y1_7H"/ M7)3DCC?B[CE_D?(\F"2!"+-*[7VIDCS=MG03%5"&A6QS`)U3E#=98VR+9$!4 M4$`#QONV]N:KNC5K>EZ:O#+XWRBNU^JM%S?WENU+5+6F9=W+CQ:P]1IP\G.4 M&3.562Y#(&0WP)M2'%O4:BP=.0@ZA`B82DCXULN*8F64.`'[5'F_+E>MQN M.ENF+(9A.480M_&U^)>SVU^VN>YJ07(/D+!JH5!(Z$MCG'$JAT'M2Q`]9A:K M4S=,TTXW9I\%V)JN-:U[ M.\V-M7:%N:6TS&%.+J\.T<5@QX6W9.5:$?"QE&O6 MT=5^DQSAN>.+]UJ`*:SU1,Y2JIB1(@@'5JT_3_Z/6[]E;DW?UR5U]2MMXM-X M5QY]GIQQP*W<6ZKNGW/],TM)**I5>C[?9%1++G)S"83Y;0AR-RPM)I.R/#I. M;&YD890PG*'0XK3DJL"HRW$`,D#8"`7?8`'QUN>_]/MA9[)O+V&2DSEL7W?$-.G+=D"'3/L0(!"C^R7;_3Q_KXDT^./859VGME<1E^;UY[E'(24=93NZ./ZY3Z/"<@9>M3> M%>.<774UE)>=QG#3S!K%UE]/ATKKN'IW"C1<[A5!0@KG'0D*&/Q%?.OLS9LX M-9JQ/"YPX^91Y2TR^ M6`Y!,\DGRAUE3;ANH<1T!1C^&6[8/'J[<&^/'-OD*R6Y)92D(ZZ06$:_E]LU MMF.N-5(A[S8HMU"XGH\L,A7XJ.7,C&U&JU!Y`\?^96$34K(],@(JLV=*'FS3;A[!O)6%:LG4A&#)0+%P MFBN90B1TAZ0`#GZ@+N>Y[3Z=;.WCR^L-GJ%7L$]"\3LT/8:5G:Y#2TC"NU\= MRSQ1Q#/G[)PXC50=)D/U(&3$%$RF^T`"`$2OP^.,,:G[0G;_`+F..Z*:Y?RA M=/BVL:E7PLOSY+Q;$"/?O_[N^]`=@E^SZOJ]?3X;[:`D/FOM><6XFRQ+04OQXQ9)LY164<93B*G-QZ;1C:%R=7JJO%%VX+C\ MQT^HFD*0%0O?3YV]DW)/"3DKQ[N><.-&2.781\:D0ZIA$ZAB]1A$1$=`:Q?X6'MSX MZY%XHO/+3E+!Q.:JGB+/F3Z!Q.Q/>VK>P8[QC8G[J!L67LH)TUZB>%D[E:'Z MD2Q;.GJ3GY1O'&],"F$HD`L#[UDW0V1VF;S<:=AGB#=%+1REY61+JS5 M_&%0M6/<3K23G'^,Y)ZY-%0S6`GK)67Q`:$.F59VNFJ4OK(IF(!>*ADSMCM\ M1&P$CD_@TAA`\&K6CXF0R#@Q#'AH!5N9HK&!4TIDL+\L9`1*/[GK$?VA'J\= M`:_?:!D'F#\Y=[[M@<2,CQ5OQEBJ+_GQP7?P%WCKK7J.7<+CLO9.1Y M#5G.R+3'F3,IV&4M$@X@URVFWD8?VK/&Q(MV`Q1GGS+=RB-:E# MY5=;]VJH"2RQ55FS,^+^-I3(^2I,J*1/6;5ROHF2-,VN<(0ZC: M&AFPB;K5.)`,JL(`DW3_`&SB'@`WK;^@9W=>;6G:?;D[75XY4P2K1M^M.G:4 M.JZO8TW+.4FNJF!IR\G.3N2.5>1W>0;^_.1HDH9&I5%BZ7"!J,&H/[J/CFB@ M^F=8R0[N'!R@LZ6`3&V*!"E['D7P_1K+/+C=_;G\+P9:8QZY*':< M_#QZA*4H>(F,(``!U`7?VB(>/L#<1\`W$0`:.W/-24U;DHV(=?C<^7LU M;X%[/;7[:ZMP4@N0G(.!50J2)VLKCK',N@=%6SJ)G(X8VNT,UB(J)PB:X]3- MDH&SK8%%`Z-NOGKZF_4^.6C3?+O-E;3VI)3CJ68 M3\RXNIK[!U%3&$PC[=]?0*Y;@LK7CT*U!?X7T)^Q MLY\G'J;7;,P`"([!N([#^R`"(B`>X`#4\+=E796,OX;4>?<>4[MVS<\BS5R9 MLZ]DC&DY7,#Y%R/+-5VR#S-A\`\>U:G5F%M*,A* MR5?;OX"04`@&,)2`V(U%`WJK&`FIW*N`W`3A)V@>?*>!.,^!,+&;<7\A1K*T ML:=!EMKR5D88D3%MUL@6))U:Y.9EGBJ2213O3KN5S%`H&/L&@)5]A#^YL[?7 M^[O#_P#?$[H"O?\`"/?W6-M_WSN07^@HF@.ANZ[@7`EN_$1]K:2Y;8QI>3N. MO(SC?DGCHW@-F'N0>,JC6"\C:QC"(8U>W5>DSG_F*MGNQB^FW+!.#IIN=Q4,5L8/WHD' MPT!^+EWVK>VEW/*^VNV<<'4+(LM8X5N>L9\QM()U_(+F)<(%^Z92'R92G*8V MMAZ(%,V^=-(M"E``%,0#;0%'5/IG*3L,]Q+@MQCI'*')7*'MW\]LBRV&X/%. M.*P>TF?0(4QHB/":8&V02;LW#9-PDLU!8J2X`6/V]S0Y2 M9@LE\L&7\1N:XC)R#3'5=-$I)P@D"C]4%#F<.=Q M$PD*0I=\[-^J&V-GZ6LED]/O2S$X+S)RE!MSIXFL%1-UI6M%1&`ZMM?5-5O2 MEWV M:R6'U[T3+JDLCF,?ZX?D6C_;_-T2\^WAZ/XG+_\`$+E$'B;(^#=O;_TM=P^( MTW8->L?_`*#T)23^1S'^>'Y$/]O\\L;=^VY\L/XDP>*G9SB<;W"+OG(FVUW( MCBO.0D(W'U<9NS5!211,(LY"P/Y=)L]FF[(P@H1H#5%,RNPJ"10\`VUHKHEEY%RC-5B_:F`W[/2NU7.41'R M`=5-F_=RV8M9BU*ERW-23?:L5[3ROY6&=LSLW6U"4:,U:\\=GCD93+C+!A%C M"Y+QNX=K+5Y4)^.B+5$,UU`.VB9:,E3,6;H[%(_0#E!0NV;MG;%M=5U-.5Q/"O^5_`@/N'0&L'/=M+N@<#>4O(_-O:)RSQCG\*' M+N$<)Q-DQOPUX^Y%E#-?EKQ.,T@5NF4IOT$E6PNI! M`ZK9NNIL4RS;YP%4P M.78W3L(>>P%"?;"X@][#@8XPIQ$M62.#60N`&%;%-LD81H-M0P%Q6XL1-JQ]QCR MEAHX2O\`9>6!I+2KR.=1QI=LSDND&#Y(JIE4$^I0IA`H`(!H"/'9/[>&2^V' MPZG...5+Q2L@624SSDO*Z$]0R3*4(G#WI*NIL(XXSK-B]-(L1A3BL()@F`G` M"F,`=0@=Z=R+MSXB[D>!&N(U:EA67)^U MX=OZ7(`T0(`U"9=TF-8#C=>YMF8^J!7"3A%=0O4JZ,<1.($V^$G:+P1Q1X\9 MXQ)D&QV;D[D;E^>RR7,S.>3UW#:[9[EK;'OXN68.#,GQY"M5-FPEW:,>R0=& M5;&646%4RQP,`%>.+.V+W>NVB,GCCM=\Q\#9DXF'>/']*XY\^:]=)"6Q"21> MN)!Q"4'(F-T@D'<695P(^DJ9@U`0$PM3+&,H8"0/'3M:\L\K\RL7=P+NO8ZC5]J^XDI'^3VG'8?H'\XZ.4EPHQ2/\`)[3&P^X/S?X? M#4*R>#I0C1/!)Q?;7@HG44N,FS.HJM/$ZL.E<#! MB@8/'_A^G4R47\1Y7+?F4QI0QTAMM^;R#;P\OT:@X6GBTB'DTBZ2?50QTAMX MAN/N\/S^>H]%KDDB2W9D_P#F2:.0>7B&WT;[Z-)81X%1TJ.$75&=0`T`T`T` MV#P\/+R^C<=QV]VXZ`;![O;O^?W_`)=`-`/+RT`T`]WT>7T?D]V@&P>[0#0# M8/:&X>W8-QV]NP>8CH"!%A[D7&.`GLA0JCO)TC$8;R0]Q9G#(D+B&^R.,L*V MV/?L(Y5')%[+#$A8F+%21;G4>-SNT&K58'#DR*`"H`'4\OS^8XSY24X^0,7:K%?9SE73G60,!1. M.*';;I)7^GL)&I,IF=:I0L0J$7'P!+LR=2!GWRP,6?K*K"4$C[`?%SO<[XH5 MI[:CRLEDQ"F4#*LA@W)F4RXJ6^ZEA"L6[NL#LNGOU!Q'/)^R0-A6KK]JU*S14=B^9JME$$UP`@@?1X.Y5XYSE:K'0XNNY3 MQSD6M5N&O#W'^9L<6'&EM?4.RO7T7!WF'C9YL4)2O2$G$K-53I*BLS=I"@Z2 M15V(($GQ\Q_*/Z]`8T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`$0# MQ'R#Q'S\@\_+QT!KPPL]EJYXG[J7&7'_`!TO=_F,^35)L#Y`B<9561Y+1.`(GH#LG@;QBS=BF6[8"^1<8J58,#=N;*F M$\FF5>1C\N.LDS5KP`ZCJ>60^846Y;, M3&BM;2Y^Y39(K^*;:H[@P?IE9'E%FH")QW)H#YWA=A>Z0?.G).;4,(<@\>XH MLW$BD8\99%Y-Y.?7_+F26[/99E>Q0TM=;I)41NTB9E+Y-F*C1!8OJJ)M M4"[%$"Y@?,?RC^O0&-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`1 M!XF?:Y.?ZGO]KK,O^J?S_AU;_6C_`.\/_7?T?+Z`E][OS_T>7].@/`7^M_`^ MS_5_+_6_R=`9#[8_P?MF\OM_9]O^7[_HT!YOK#_D_K]WT:`\2OL_A?9'^+_G 8!Y?Y/].@,C]L/X?F/G]O[/L^G^C0'__9 ` end -----END PRIVACY-ENHANCED MESSAGE-----